TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Granules India Ltd.

GRANULES on NSE · 19 Nov 2026

NIFTY 500

801.20 ▲ +0.46 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Options Guidance & governance

Filings

33 filings of GRANULES since January 2025.

board outcome 13, transcript 9, presentation 8, results 2, dividend 1

FiledTypeSubject
06 Nov 2026transcript
Capex, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 2, 2026, under Regulation 46 of the SEBI LODR Regulations.

Management said Q2 revenue grew 20% year-on-year to INR15,600 million and PAT rose 39% year-on-year to INR1,818 million; EBITDA was INR3,376 million, up 21% year-on-year, with EBITDA margin at 21.6%.

Management said an FDA cGMP inspection of the Gagillapur facility from October 19 to October 30, 2026 ended with a Form 483 containing eleven observations, which it said do not relate to data integrity, cross-contamination or facility upkeep, and that the response will be submitted within 15 business days.

Management said Q2 gross margin was 64.4%, down 134 basis points year-on-year, due to higher input costs linked to conflicts in West Asia.

CFO reported net cash of INR8,280 million at quarter end versus net debt of INR1,012 million in Q1 FY27, and capex of INR1,304 million in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Nov 2026presentation
Results
Granules India Limited has informed the Exchange about Presentation
AI summary

Granules India filed an earnings presentation for Q2 FY27 and H1 FY27 (quarter and half year ended September 30, 2026), alongside unaudited results submitted on November 2, 2026.

Management (Chairman & MD Dr. Krishna Prasad Chigurupati) said quarterly revenue crossed ₹1,500 Cr in Q2 FY27 with EBITDA of ₹338 Cr, and that cost pressures from West Asia tensions will persist.

Q2 FY27 revenue was ₹15,600 Mn (+20% YoY), EBITDA ₹3,376 Mn (+21% YoY, 21.6% margin), and PAT ₹1,818 Mn (+39% YoY); gross margin was 64.4%, down 134 bps YoY.

Management stated the company holds net cash of ₹828 Cr after receipt of balance warrant proceeds, and that it recently concluded a US FDA audit at the Gagillapur site, with observations it believes can be addressed through responses and corrective actions.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Nov 2026board outcome
Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
AI summary

Board of Granules India Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 (Board meeting held November 2, 2026, 3:00 PM to 4:40 PM); Limited Review Report of statutory auditors S.R. Batliboi & Associates LLP enclosed.

Standalone revenue from operations for Q2 FY27 was Rs 9,478.21 million, against Rs 8,018.77 million in Q1 and Rs 8,916.13 million in Q2 of the prior year.

Standalone net profit for the quarter ended September 30, 2026 was Rs 1,085.16 million, against Rs 717.46 million in the previous quarter and Rs 1,206.13 million in the corresponding quarter last year.

Standalone basic EPS for the quarter was Rs 4.31 (not annualised); half-year net profit was Rs 1,802.62 million.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
06 Oct 2026transcript
Capex, Guidance, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its webinar "Granules India 2.0 – Comprehensive Transformation Underway", held September 29, 2026, under Regulation 46 of the SEBI LODR Regulations.

Dr. Krishna Prasad Chigurupati (CMD) said the company returned to growth in FY26 after nearly three years of flat performance, and aims over the next three to four years for a substantially larger business with faster earnings growth.

Ms. Priyanka Chigurupati (ED) said complex generics rose from 1% of overall revenue in fiscal 20 to 33% in fiscal 26, and the company has filed two sole first-to-file ANDAs; the US (about 75% of revenue) remains the anchor market.

Mr. Vijay Ramanavarapu (President, Granules Pharmaceuticals, Inc.) said Granules is now the third largest US controlled substance manufacturer by value per IQVIA data, up from eighth in July 2025.

Mr. Sanjay Kumar (CEO, Senn Tides India) said the peptide CDMO targets about USD 50 million annual revenue run rate in three years and USD 100 million in five years, with profitability targeted in FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
27 Jul 2026transcript
Capex, Guidance, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q1 FY27 earnings conference call held on July 21, 2026, under Regulation 46 of the SEBI LODR Regulations, and uploaded it on its website.

Management said Q1 FY27 revenue rose 22% year-on-year to INR1,477 crore, with gross margin at 65.6%, EBITDA up 37% to INR339 crore (margin 22.9%) and profit after tax up 60% to INR180 crore; ROCE was 18%.

Management said net debt to EBITDA was 0.07x and operating cash generation was over INR387 crore in the quarter; net debt stood at INR1,012 million versus INR4,021 million at FY26 close.

Management said capex for the year is still guided at INR600 crore, with INR89 crore spent so far, and that it expects EBITDA margins to remain in the 22% to 23% range.

Management said the Gagillapur site remains the only one of eight facilities without a clean EIR, and that remediation work is essentially complete.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Jul 2026presentationGranules India Limited has informed the Exchange about PresentationNSE copy
21 Jul 2026board outcomeGranules India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.NSE copy
05 May 2026transcript
Capex, Guidance, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q4 and FY26 (year ended March 31, 2026) earnings conference call held April 29, 2026, uploaded on the company website.

FY26 revenue stood at INR53,656 million, up 20% year-on-year; Q4 FY26 revenue was INR14,706 million, up 23% year-on-year and 6% sequentially (management said this was the sixth consecutive quarter of sequential growth).

FY26 EBITDA was INR11,851 million with margin of 22.1%; Q4 FY26 EBITDA was INR3,521 million, margin 23.9% (management said Q4 was the first quarter of positive EBITDA in the acquired peptide CDMO business).

FY26 PAT grew 19% year-on-year to INR5,950 million post exceptional items; net debt reduced to INR4,021 million from INR7,061 million in FY25, per management.

Management said the company expects peptide CDMO to be PAT positive on an annual basis in FY27, while quarterly results may vary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Apr 2026board outcome
Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Granules India Limited filed the outcome of its board meeting held on April 29, 2026 (11.00 AM to 12.30 PM).

The board approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, prepared under Ind-AS.

The statutory auditor, S R Batliboi & Associates LLP, issued an unmodified opinion on both the standalone and consolidated results.

The filing does not state revenue, profit, dividend or other figures; those are in the enclosed results.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Apr 2026presentation
Results
Granules India Limited has informed the Exchange about Presentation
AI summary

Granules India filed its earnings presentation for Q4 and FY26 (year ended March 31, 2026), following audited results submitted on April 29, 2026.

FY26 revenue was ₹53,656 Mn, up 20% YoY; EBITDA was ₹11,851 Mn (22.1% margin, up 100 bps YoY), including an EBITDA loss of ₹445 Mn in Ascelis; PAT was ₹5,950 Mn (11.1% margin, up 19% YoY).

Gross margin rose 355 bps YoY to 65.0%; ROCE was 17.6% (16.6% in FY25); net debt/EBITDA was 0.34x (0.75x in FY25).

Management said FY26 marked a landmark year, surpassing the ₹50,000 Mn revenue milestone with the highest gross margin, and that North America remained the core growth engine while Europe nearly doubled and the CDMO platform opened a new revenue vertical.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Apr 2026board outcome
Dividend / buy-back, Results
Granules India Limited has informed the Exchange regarding Outcome of Board Meeting held on April 29, 2026.
AI summary

Board of Granules India Limited approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, under Ind-AS.

The Board recommended a final dividend of Rs. 1.75 per share (face value Re. 1), representing 175% of paid-up equity share capital, for FY 2025-26; record date July 30, 2026.

The 35th Annual General Meeting is fixed for Thursday, August 06, 2026.

The board meeting commenced at 11.00 A.M and concluded at 12.30 P.M.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Apr 2026board outcome
Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
AI summary

Granules India Limited's Board approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026, prepared under Ind-AS.

The statutory auditors, S R Batliboi & Associates LLP, issued an unmodified opinion on both the standalone and consolidated results for FY ended March 31, 2026.

The Board meeting commenced at 11.00 A.M. and concluded at 12.30 PM on April 29, 2026.

The filing does not state revenue, profit, dividend or other financial figures; the results were enclosed separately and are not part of these pages.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 Jan 2026transcript
Capex, Guidance, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q3 and 9M FY26 earnings conference call held on January 23, 2026, uploaded to the company website.

Management reported Q3 FY26 revenue of INR13,879 million, up 22% year-on-year and 7% sequentially, with EBITDA of INR3,081 million (22.2% margin) and gross margin of 63.9%.

Management said Ascelis Peptides recorded an EBITDA loss of INR248 million in Q3 due to planned maintenance and higher execution activity, and expects a meaningful improvement in Q4 FY26.

Management said the company is in discussions with the US FDA after a post-warning letter meeting in early January at the Gagillapur facility, with additional documentation to be submitted and no timeline given for reinspection.

Net debt was INR10,151 million and capex was INR1,298 million in Q3 FY26; management referred to a preferential issue approved at an EGM.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Jan 2026presentation
Capex, Rating, Results
Granules India Limited has informed the Exchange about Presentation
AI summary

Granules India filed its Q3FY26 earnings presentation (January 23, 2026), accompanying unaudited results for the quarter and nine months ended December 31, 2025.

Q3FY26 revenue was ₹13,879 Mn, up 22% YoY and 7% QoQ; EBITDA was ₹3,081 Mn (22.2% margin) and PAT was ₹1,502 Mn (10.8% of sales).

EBITDA included a loss of ₹248 Mn from Ascelis Peptides in Q3FY26, per the presentation.

Capex was ₹1,298 Mn in Q3FY26 versus ₹2,112 Mn in Q2FY26; cash flow from operations was ₹2,187 Mn versus ₹1,937 Mn in Q2FY26.

ICRA upgraded the company's credit rating from AA- to AA; the India rating was reaffirmed at AA- with positive outlook.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Jan 2026board outcome
Acquisition, Capex, Legal, Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
AI summary

Granules India Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, and the board meeting ran from 3.00 PM to 4.40 PM on January 23, 2026.

Standalone revenue from operations for Q3 FY26 (quarter ended December 31, 2025) was Rs 8,953.18 million, against Rs 8,421.96 million a year earlier; standalone net profit was Rs 1,115.82 million, against Rs 901.11 million a year earlier.

Standalone revenue from operations for the nine months ended December 31, 2025 was Rs 25,971.39 million, against Rs 22,621.37 million a year earlier; standalone net profit was Rs 3,016.80 million, against Rs 2,252.82 million.

An exceptional item of Rs 121.60 million in the nine months ended December 31, 2025 relates to transaction costs for the acquisition of Senn Chemicals AG.

The board and shareholders approved capital raising of up to Rs 14,625.00 million through convertible warrants and up to Rs 3,000.00 million through preferential equity issue at Rs 585 per share, subject to regulatory approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
23 Dec 2025board outcome
Capex, Dividend / buy-back, Legal
Granules India Limited has informed the Exchange regarding Board meeting held on December 23, 2025.
AI summary

Board of Granules India Limited approved a preferential issue of up to 2,50,00,000 convertible warrants at Rs. 585 per warrant, aggregating up to Rs. 1,462.50 crores, to Promoter group and Non-Promoter investors, convertible into equity shares of Rs. 1 face value within 18 months of allotment.

Board also approved a preferential issue of up to 51,28,205 equity shares at Rs. 585 per share, aggregating up to Rs. 300 crores, to Non-Promoter investors.

Issue is subject to regulatory and shareholder approval at an Extra-Ordinary General Meeting to be held on January 22, 2026 through video conferencing.

Of the warrant consideration, 25% is payable on application and 75% on conversion; the relevant date under SEBI ICDR Regulations is December 23, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Nov 2025transcript
Acquisition, Capex, Guidance, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Management said the Gagillapur site remediation is in its final stages, with a US FDA meeting granted for January 2026 and reinspection to follow; the Genome Valley GLS site received its first US FDA approval for a product.

Q2 FY'26 revenue was Rs. 12,970 million, up 34% year-on-year from Rs. 9,666 million and up 7% sequentially; gross margin was 65.7%, and EBITDA was Rs. 2,782 million (21.5% of sales).

Net debt was Rs. 10,241 million and Q2 capex was Rs. 2,112 million; cash flow from operations was Rs. 1,937 million.

Management said Ascelis Peptides (including Senn Chemicals) is expected to turn profitable in Q4 FY'26 and targets FY'27 as its first fully synergised and profitable year; it declined to give quarterly or revenue guidance.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025presentation
Acquisition, Capex, Legal, Results
Granules India Limited has informed the Exchange about Presentation
AI summary

Granules India filed its Q2FY26 earnings presentation (13 November 2025) alongside unaudited results for the quarter and half year ended 30 September 2025.

Q2FY26 revenue was ₹12,970 Mn, up 7% QoQ and 34% YoY; PAT was ₹1,306 Mn (10.1% of revenue), up 16% QoQ and 34% YoY.

EBITDA before exceptional items was ₹2,782 Mn (21.5% margin), against ₹2,467 Mn in Q1FY26 and ₹2,033 Mn in Q2FY25; management said this includes a ₹200 Mn EBITDA loss from Ascelis Peptides.

Management said YoY sales growth was driven mainly by formulations in North America and Europe; ROCE was 16.2%, cash from operations ₹1,937 Mn and capex ₹2,112 Mn.

R&D expenses were ₹705 Mn (5.4% of sales); the company reported 91 US FDA approvals to date and 3 ANDA filings in Q2FY26.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025board outcome
Acquisition, Capex, Results
Granules India Limited has informed the Exchange regarding Outcome of Board Meeting held on November 13, 2025.
AI summary

Granules India's board on November 13, 2025 approved unaudited consolidated and standalone results for the quarter and half year ended September 30, 2025.

The board approved acquiring a 100% equity stake in newly incorporated Optus 1039 GmbH, Frankfurt, Germany, for EUR 28,400 (about INR 29,09,296), to be completed by end of December 2025, for B2C entry in Europe.

The board approved acquiring up to 26% equity in Renpow Narayankhed Private Limited, a related-party SPV of Ecoren Energy India, for up to INR 13.74 Crores in four tranches within a year, to secure captive renewable power of up to 10.20 MW.

The board approved acquiring up to 26% equity in Renpow Kalyandurg Private Limited, another Ecoren SPV, for up to INR 3.50 Crores.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Nov 2025board outcome
Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Granules India Limited filed the outcome of its board meeting held on November 13, 2025, approving unaudited standalone and consolidated results for the quarter and half year ended September 30, 2025.

Standalone revenue from operations for Q2 FY26 (quarter ended Sep 30, 2025) was Rs 8,916.13 million, against Rs 5,679.91 million a year earlier; half-year revenue was Rs 17,018.21 million versus Rs 14,199.41 million.

Standalone net profit for the quarter was Rs 1,206.13 million, against Rs 413.92 million a year earlier; half-year profit was Rs 1,900.98 million versus Rs 1,351.71 million.

Basic EPS for the quarter was Rs 4.97 (not annualised), against Rs 1.71 a year earlier.

The filing includes the statutory auditor's limited review report (S.R. Batliboi & Associates LLP), which reports no material misstatement.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Aug 2025transcript
Acquisition, Capex, Guidance, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q1 FY26 earnings conference call held on August 12, 2025, under Regulation 46 of the SEBI LODR Regulations.

Management said remediation at the Gagillapur facility is in its final stages after a US FDA warning letter, with a meeting and re-inspection to be sought in September 2025 and a re-audit clearance possibly taking until end of December.

Management reported Q1 FY26 revenue of Rs.12,101 million (up 3% year-on-year), gross margin of 64.9%, EBITDA of Rs.2,467 million (20.4% of sales), net debt of Rs.9,480 million and capex of Rs.1,137 million.

Management said the Senn Chemicals AG acquisition and the Ascelis Peptides platform are part of a move into peptides and CDMO, with an IIT Hyderabad R&D facility due by October 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2025presentation
Acquisition, Capex, Legal, Results
Granules India Limited has informed the Exchange about Investor Presentation
AI summary

Granules India filed its Q1 FY26 earnings presentation (August 12, 2025), following its unaudited Q1 FY26 results submitted the same day.

Revenue was ₹12,101 Mn, up 3% YoY and 1% QoQ; gross margin was ₹7,850 Mn (64.9%); EBITDA before exceptional items was ₹2,467 Mn (20.4% margin); PAT was ₹1,126 Mn (9.3% margin), down 16% YoY and 26% QoQ.

Management said PAT was lower on account of exceptional items, mainly expenses related to ongoing litigation settlements; EBITDA was impacted by higher manpower costs following consolidation of Senn Chemicals AG (revenue ₹291 Mn).

Management reported cash from operations of ₹2,806 Mn and capex of ₹1,137 Mn, and noted USFDA audits of Bonthapally, GPI and GLS were cleared with one minor observation each.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Aug 2025board outcome
Acquisition, Legal, Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AI summary

Board of Granules India Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 (meeting held August 12, 2025, 11.00 A.M. to 12.30 P.M.).

Consolidated total revenue from operations for Q1 FY26 was Rs 12,101.06 million, versus Rs 11,974.29 million in the previous quarter (Mar 2025) and Rs 11,798.65 million in the year-ago quarter (Jun 2024).

Consolidated net profit for the quarter was Rs 1,126.36 million, versus Rs 1,520.31 million in the previous quarter and Rs 1,346.48 million in the year-ago quarter; basic EPS was Rs 4.64.

Exceptional items (net) for the quarter were Rs (259.11) million, including Senn Chemicals AG acquisition transaction costs of Rs 121.60 million and a gain of Rs 104.25 million on disposal of the US Pharma Ltd investment.

The filing notes the Gagillapur facility's USFDA warning letter (February 2025) and the voluntary pause in manufacturing and distribution from September 2024, which affected revenue and expenses in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Jun 2025transcript
Acquisition, Capex, Guidance, Legal, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q4 and FY2025 earnings conference call held on May 28, 2025, uploaded to its website.

Management said the Gagillapur facility received a US FDA warning letter on February 26, 2025, with remediation slowing operations, impacting Q4 output for another quarter or two.

Q4 FY25 revenue was Rs. 11,974 million (up 2% YoY); FY25 revenue was Rs. 44,816 million versus Rs. 45,064 million in FY24.

Q4 FY25 EBITDA was Rs. 2,524 million (21.1% of sales) versus Rs. 2,557 million (21.7%) in Q4 FY24; FY25 EBITDA was Rs. 9,452 million, up 10%.

Management said net debt was Rs. 7,061 million at March 2025 and the company acquired Swiss CDMO Senn Chemicals, with acquisition formalities completed in April 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 May 2025presentation
Acquisition, Capex, Legal, Results
Granules India Limited has informed the Exchange about Investor Presentation
AI summary

Granules India Limited filed an earnings presentation for Q4 FY25 and FY25 on May 28, 2025, following its audited results for the quarter and year ended March 31, 2025.

Q4 FY25 revenue was Rs 11,974 Mn, up 1.9% from Rs 11,758 Mn... (Y-o-Y growth shown as 2%), with gross margin at 63.4% and EBITDA of Rs 2,524 Mn (EBITDA margin 21.1%) and PAT of Rs 1,520 Mn (PAT margin 12.7%).

Management said Q4 FY25 PAT included a cyber security business interruption insurance claim of Rs 308 Mn (pre-tax), and that professional expenses rose on consultancy for remediation of USFDA observations.

Management reported operating cash flow of Rs 3,183 Mn and a net debt to EBITDA ratio of 0.75x.

Management stated the Senn Chemicals AG (peptide CDMO) acquisition was completed on April 10, 2025 for 100%, the GLS Phase II 7.5 Bn formulation dosages facility was inaugurated, and a Lisdexamfetamine Dimesylate Capsule approval was received.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 May 2025dividend
Dividend / buy-back, Results
Granules India Limited has informed the Exchange that Board of Directors at its meeting held on May 28, 2025, recommended Final Dividend of Rs. 1.50 per equity share.
AI summary

Board of Granules India Limited approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025 under Ind-AS.

Board recommended a final dividend of Rs. 1.50 per share (face value Re. 1), representing 150% of paid-up equity share capital, for FY 2024-25; record date July 31, 2025.

Board fixed the 34th Annual General Meeting for Thursday, August 7, 2025.

Board approved appointment of M/s. Saurabh Poddar & Associates as Secretarial Auditor for 5 consecutive years, from conclusion of the 34th AGM to conclusion of the 39th AGM, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
28 May 2025board outcome
Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
AI summary

Board of Granules India Limited approved the audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2025, prepared under Ind-AS.

The statutory auditors, S R Batliboi & Associates LLP, issued an unmodified opinion on both the standalone and consolidated results for the financial year ended March 31, 2025.

The auditor's report notes that the Q4 figures are the balancing figure between audited full-year figures and published unaudited year-to-date figures up to Q3, which were subjected to limited review.

The Board meeting ran from 11.00 A.M. to 1.00 P.M. on May 28, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Mar 2025board outcome
Acquisition
Granules India Limited has informed the Exchange regarding Board meeting held on March 25, 2025.
AI summary

Granules India's board approved an internal restructuring plan involving its existing wholly owned subsidiaries in the USA.

Under the plan, Granules USA, Inc. (GUSA) will transfer its business and substantially all of its net assets to Granules Pharmaceutical, Inc. (GPI), also a wholly owned subsidiary.

The company says the plan will reduce the number of legal entities, simplify legal, tax and operational structures, and create a unified holding structure.

The restructuring does not change the ultimate ownership of subsidiaries or the nature of US business, and will be accounted for as a common control transaction at carrying values under Ind AS 103.

The company states there is no benefit to promoter, promoter group or group companies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
21 Feb 2025board outcome
Acquisition, Capex
Granules India Limited has informed the Exchange regarding Board meeting held on February 21, 2025.
AI summary

Board of Granules India approved the acquisition of a 100% equity stake in Senn Chemicals AG, a Switzerland-based peptide CDMO, for a cost of CHF 20 million (about INR 1,925 million, excluding charges and expenses), paid in cash.

Senn Chemicals AG had revenues of CHF 26.3 million in CY22, CHF 26.9 million in CY23 and an estimated CHF 19.6 million in CY24.

The acquisition is expected to be completed in the first half of calendar year 2025 and is subject to Swiss Code of Obligations and Lex Koller requirements.

The Board also approved incorporation of a wholly owned subsidiary in India to hold the Senn Chemicals AG acquisition, with authorised share capital of Rs. 500 crore and paid-up share capital of Rs. 200 crore, subject to regulatory approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Jan 2025transcript
Capex, Guidance, Legal, Management change, Results
Granules India Limited has informed the Exchange about Transcript
AI summary

Granules India filed the transcript of its Q3 and 9M FY25 earnings conference call held January 24, 2025.

Management said the USFDA classified the August-September 2024 inspection of the Gagillapur facility as Official Action Indicated (OAI), with six Form 483 observations; about 90% of CAPAs are complete and the rest are on track for closure by March 2025.

Q3 FY25 revenue was INR 11,377 million (down 2% year on year), gross margin 61.7%, EBITDA INR 2,303 million (20.2% of sales), and net debt INR 8,289 million, as stated by the CFO.

Management said FY25 revenue growth cannot be quantified today, but expects a CAGR of around 20% plus over time; Q3 costs included about $3 million of airfreight, failure-to-supply and consultancy expenses, with a little above 50% expected to recur in Q4.

Management said no reinspection date has been received from the USFDA and that new product approvals from Gagillapur may be impacted until the OAI status is resolved.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025results
Legal, Results
Integrated Filing-Financials for the Quarter ended on December 31, 2024.
AI summary

Granules India Limited filed its integrated financial filing for the quarter and nine months ended December 31, 2024, including unaudited standalone results (Ind AS, reviewed by S.R. Batliboi & Associates LLP with unmodified review conclusion).

Q3 FY25 (quarter ended Dec 31, 2024): total revenue from operations Rs 8,421.96 million; profit before tax Rs 1,186.01 million; net profit Rs 901.11 million; basic EPS Rs 3.72 (not annualised).

Nine months ended Dec 31, 2024: total revenue from operations Rs 28,149.00 million (vs Rs 28,066.59 million... see note); profit before tax Rs 3,005.34 million; net profit Rs 2,252.82 million; basic EPS Rs 9.29.

The company said a voluntary pause of manufacturing at its Gagillapur, Hyderabad facility after a USFDA inspection (Aug 26 to Sep 6, 2024, six observations) significantly impacted revenue and profitability for the nine months; manufacturing resumed in a staggered manner in October 2024.

In December 2024, USFDA classified the inspection as "Official Action Indicated" (OAI); the company said it is taking necessary steps.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025presentation
Legal, Results
Granules India Limited has informed the Exchange about Investor Presentation
AI summary

Granules India filed an investor/analyst earnings presentation for Q3 FY25 (quarter and nine months ended December 31, 2024), following its unaudited results submitted the same day.

Q3 FY25 revenue was Rs 11,377 Mn, up 61.7% year-on-year... [see note]

Q3 FY25 gross margin was 61.7%, EBITDA Rs 2,303 Mn (20.2% margin) and PAT Rs 1,176 Mn, versus Rs 2,505 Mn EBITDA (21.7% margin) and PAT Rs 1,257 Mn in Q3 FY24.

Management said production at the Gagillapur plant was voluntarily paused in Sep-24 for risk assessment on US FDA observations and resumed in a staggered manner in October.

Management cited higher freight, FTS and professional expenses after the recent USFDA inspection, continued R&D investment, and price erosion and lower demand in API/PFI as pressures on margins.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jan 2025results
Legal, Results
Granules India Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
AI summary

Granules India Limited filed unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 24, 2025, with Limited Review Reports from S.R. Batliboi & Associates LLP.

Standalone revenue from operations for Q3 FY25 was Rs 8,421.96 million, against Rs 5,679.91 million in Q2 (September 30, 2024 quarter); nine-month revenue from operations was Rs 28,149.00 million... Q3 profit for the period was Rs 901.11 million, against Rs 413.92 million in the prior quarter.

Nine-month standalone profit for the period was Rs 2,252.82 million, against Rs 3,387.02 million in the nine months ended December 31, 2023.

The company said a voluntary pause of manufacturing and distribution at its Gagillapur, Hyderabad facility, after a USFDA inspection (August 26 to September 6, 2024, with six observations), significantly impacted revenue and profitability for the nine months; in December 2024 USFDA classified the inspection as "Official Action Indicated" (OAI).

The company allotted 125,000 equity shares on exercise of employee stock options during the quarter and nine months.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in